- Report
- November 2025
- 198 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- November 2025
- 183 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 373 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 282 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- April 2025
- 125 Pages
United States
From €2846EUR$3,250USD£2,471GBP
- Report
- February 2025
- 315 Pages
Global
From €4203EUR$4,799USD£3,648GBP
- Report
- January 2025
- 456 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- January 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Book
- August 2021
- 312 Pages
- Book
- January 2024
North America
Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more
